Functional Brands Inc. Announces Launch of GLP-Squared Injection
Rhea-AI Summary
Functional Brands (NASDAQ: MEHA) launched GLP-Squared Injection, a dual-peptide formulation combining Semaglutide and Tirzepatide, available exclusively through its Tru2u.health digital platform effective May 6, 2026. The therapy is clinician-prescribed, requires telehealth consultation and lab screening, and is fulfilled via the Tru2u.health ecosystem.
The company positions GLP-Squared as a precision, clinician‑supervised option aiming to deliver combined appetite regulation, glycemic control, and adipose reduction; access is limited to qualifying Tru2u.health members after provider approval.
Positive
- Dual-peptide formulation combining Semaglutide and Tirzepatide
- Platform-exclusive distribution through Tru2u.health
- Clinician-supervised protocol with telehealth consultations and lab screening
Negative
- Member-only availability limits access to qualifying Tru2u.health members
- Not available via retail or mail-order pharmacies, restricting traditional channels
News Market Reaction – MEHA
On the day this news was published, MEHA declined 6.91%, reflecting a notable negative market reaction. Argus tracked a peak move of +15.8% during that session. Argus tracked a trough of -9.5% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $154K from the company's valuation, bringing the market cap to $2.08M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Platform expansion | Positive | -10.5% | Tru2u.health added clinically supervised NAD+ therapy to its offerings. |
| Apr 22 | Tech partnership | Positive | +7.2% | Strategic partnership with partnrup.ai to optimize AI-driven partner marketing. |
| Apr 17 | Product launch | Positive | -4.1% | Launch of Kirkman Weight Loss Support Bundle targeting digestion and metabolism. |
| Mar 30 | Earnings report | Neutral | -3.3% | Q4 and 2025 results showed slight revenue growth, profitability, but margin compression. |
| Mar 20 | Distribution deal | Positive | +0.8% | Expanded global distribution of P2i prenatal via iHerb across multiple regions. |
Recent product and platform launches often saw muted or negative next-day moves, while the AI partnership drew a positive reaction, indicating inconsistent pricing of growth initiatives.
Over the last few months, Functional Brands has focused on expanding Tru2u.health and its product lineup. On Mar 20, it broadened international access for P2i by Kirkman, followed by Q4 and full-year 2025 results on Mar 30 showing profitability but margin pressure. Subsequent launches on Apr 17 (weight loss bundle) and Apr 29 (NAD+ therapy) expanded its metabolic and wellness offerings, with mixed share reactions. The new GLP-Squared dual-peptide launch continues this strategy of layering differentiated therapies onto the Tru2u.health platform.
Market Pulse Summary
The stock moved -6.9% in the session following this news. A negative reaction despite the GLP-Squared launch would fit prior patterns where product and platform expansions on Apr 17 and Apr 29 were followed by weak price performance. Regulatory filings flag going-concern risks, secured convertible notes, and a wide reverse split authorization up to 1-for-250, which may weigh on sentiment. Investors have previously discounted growth narratives amid balance sheet complexity and Nasdaq bid-price deficiency concerns.
Key Terms
semaglutide medical
tirzepatide medical
glp-1 receptor agonist medical
gip medical
telehealth technical
glp-1 medical
AI-generated analysis. Not financial advice.
Proprietary Semaglutide + Tirzepatide Dual-Peptide Formulation Now Available Exclusively Through the Tru2u.health Platform
Lake Oswego, Portland--(Newsfile Corp. - May 6, 2026) - Functional Brands Inc. (NASDAQ: MEHA), a pioneer in next-generation health and wellness solutions, today announced the official launch of GLP-Squared Injection, its groundbreaking dual-peptide injectable combining Semaglutide and Tirzepatide in a single, synergistic formulation. GLP-Squared is now exclusively available to members of the Company's flagship digital health platform, Tru2u.health.
"The introduction of GLP-Squared Injection is a transformational milestone for Functional Brands and the members of Tru2u.health. By combining two of the most clinically effective peptides in metabolic medicine into a single, physician-guided protocol, we are offering our members a powerful new tool to achieve their health goals. Tru2u.health was built to be the home of innovation in personalized health, and GLP-Squared exemplifies exactly that commitment," said Eric Gripentrog, CEO of Functional Brands Inc.
A New Standard in GLP-1-Based Metabolic Therapy
GLP-Squared Injection represents a significant advancement in metabolic and weight-management medicine. By combining Semaglutide-a proven GLP-1 receptor agonist-with Tirzepatide's dual GLP-1/GIP receptor agonist activity, the formulation is designed to deliver amplified appetite regulation, improved glycemic control, and enhanced adipose tissue reduction through complementary and synergistic mechanisms of action.
The goal of offering patients a precision-optimized, clinician-supervised peptide therapy that goes beyond what single-agent GLP-1 products can achieve.
Key Highlights: GLP-Squared Injection
Dual-Mechanism Action: Combines Semaglutide (GLP-1 agonist) with Tirzepatide (GLP-1 + GIP dual agonist) for a multi-receptor metabolic impact that addresses appetite, insulin sensitivity, and fat metabolism simultaneously.
Precision Peptide Formulation: Clinically calibrated dosing ratios developed to maximize synergy while maintaining an individualized safety profile for each Tru2u.health member.
Clinician-Supervised Protocol: GLP-Squared is prescribed and monitored by licensed healthcare providers through the Tru2u.health telehealth infrastructure, ensuring medically appropriate oversight at every step.
Platform-Exclusive Access: GLP-Squared Injection is exclusively available through Tru2u.health, underscoring the Company's commitment to integrating cutting-edge therapeutics within its personalized digital health ecosystem.
Streamlined Member Experience: From initial consultation and labs to prescription fulfillment and ongoing coaching, members receive end-to-end support directly through the Tru2u.health platform.
Tru2u.health: The Platform Powering Personalized Health at Scale
Tru2u.health is Functional Brands' proprietary digital health platform designed to connect members with licensed clinicians, evidence-based therapeutics, and personalized wellness protocols-all in one place. Tru2u.health serves as the exclusive conduit for GLP-Squared Injection, allowing members to:
Complete telehealth consultations with credentialed providers
Access required laboratory screening and results review
Receive GLP-Squared prescriptions with direct fulfillment
Engage with ongoing metabolic coaching, nutrition guidance, and progress monitoring
Benefit from a fully integrated, data-driven health journey personalized to their biology and goals
The launch of GLP-Squared on Tru2u.health marks a pivotal expansion of the platform's therapeutic offerings, reinforcing its position as a premier destination for members seeking clinically sophisticated, results-driven health optimization.
Addressing a Multi-Billion Dollar Market Opportunity
The global GLP-1 therapy market is among the fastest-growing segments in healthcare, with demand for Semaglutide and Tirzepatide-based therapies continuing to accelerate. Functional Brands is strategically positioned to capture meaningful market share through the Tru2u.health platform, which offers a differentiated, end-to-end member experience that commodity pharmacy channels cannot replicate.
GLP-Squared Injection further distinguishes Tru2u.health by offering a proprietary dual-peptide option not available through traditional retail or mail-order pharmacy routes, creating a meaningful competitive moat and a compelling driver of member acquisition and retention.
Availability
GLP-Squared Injection is available immediately to qualifying Tru2u.health members following clinician evaluation and approval. Interested individuals may visit www.Tru2u.health to begin their intake, complete telehealth onboarding, and determine eligibility for the GLP-Squared protocol.
About Functional Brands Inc. (MEHA)
Functional Brands Inc. (NASDAQ: MEHA) is a health and wellness company dedicated to delivering innovative, evidence-based therapeutic solutions through its proprietary digital platform, Tru2u.health. The Company's mission is to make clinically meaningful health optimization accessible, personalized, and scalable for every member. Functional Brands develops and distributes a curated portfolio of functional health products, peptide therapies, and telehealth services designed to support metabolic health, longevity, and overall wellbeing.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those implied by the forward-looking statements. Functional Brands Inc. undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
INVESTOR & MEDIA CONTACT
Functional Brands Inc. | Investor Relations
ir@functionalbrands.com
www.Tru2u.health | NASDAQ: MEHA
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296153